Halozyme Therapeutics Raises 2026 Guidance After Hypercon, Surf Bio Deals Extend Platform Into 2040s

Core Insights - Halozyme Therapeutics is expanding its portfolio with the acquisition of Hypercon and Surf Bio, enhancing its capabilities in subcutaneous (SC) drug delivery technologies [4][5][6] - The company expects significant revenue growth, with preliminary 2025 total revenue estimates between $1.385 billion and $1.4 billion, representing a 36% to 38% increase over 2024 [8] - Halozyme has raised its 2026 guidance, projecting total revenue between $1.71 billion and $1.81 billion, with royalty revenue between $1.13 billion and $1.17 billion [17] Acquisition and Technology Expansion - The acquisition of Surf Bio adds a second hyperconcentration technology, which is expected to be clinic-ready by the end of 2027 or early 2028 [4][7] - Hypercon technology is anticipated to be clinic-ready in 2026, with two partners expected to initiate Phase I studies by the end of 2026 [5][7] - The company now has three royalty-bearing SC delivery technologies, expanding its opportunity set into the mid-2040s [5][6] Financial Performance and Projections - Halozyme's 2025 royalty revenue is projected to be between $865 million and $870 million, reflecting a growth of 51% to 52% over 2024 [8] - For 2026, the company expects to exceed $1 billion in royalty revenue, a year earlier than previously projected [9] - Long-term projections indicate total revenue exceeding $2 billion by 2028, with royalty revenue between $1.46 billion and $1.51 billion, representing a CAGR of 26% to 28% from 2024 to 2028 [11] Product Development and Market Strategy - The company anticipates six new ENHANZE products entering Phase I in 2026, increasing the development portfolio to 13 products [13] - Major product drivers include DARZALEX and VYVGART Hytrulo, with projected sales of $14.3 billion and $4.15 billion respectively for 2025 [13] - Halozyme is exploring additional M&A opportunities to enhance its drug delivery technology and revenue growth [15] Profitability and Operational Efficiency - Halozyme aims for a gross margin above 80% and an operating margin greater than 60% during the 2026–2028 period [12] - The company projects free cash flow to exceed 70% of EBITDA, indicating a strong focus on operational efficiency [12]